A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors

• Published in: Annals of oncology Vol. 29; no. 7; pp. 1561 - 1568
• Main Authors: Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J.V., Kapoun, A.M., Xu, L., Munster, P.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2018; Oxford University Press
• Subjects: Adult; Aged; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Antineoplastic Agents, Immunological - pharmacokinetics; Antineoplastic Agents, Immunological - therapeutic use; brontictuzumab; Cohort Studies; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm - drug effects; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - pathology; Neoplasms - drug therapy; Neoplasms - pathology; Notch1; OMP-52M51; Prognosis; Receptor, Notch1 - antagonists & inhibitors; Receptor, Notch1 - immunology; Salvage Therapy; solid tumors; Survival Rate; targeted therapy; Tissue Distribution; targeted therapy; OMP-52M51; brontictuzumab; Notch1; solid tumors

Brontictuzumab is a monoclonal antibody that targets Notch1 and inhibits pathway activation. The purpose of this first-in-human study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, immunogenicity and preliminary efficacy of brontictuzumab in patients with solid tumors....